Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Oct 18 2023

Full Issue

Trial Data Show Antiviral Pill May Help With Covid's Loss Of Smell, Taste

The pill, ensitrelvir, may help shorten the symptoms that many patients experience. The drug is not reserved for those at high risk of severe illness, and is the first that may alleviate the effects. Separately, a study shows mRNA covid vaccines strongly protect young kids.

Nature: Smell Loss From COVID Fades Quickly With Help Of New Pill

New clinical-trial data suggest that an antiviral pill called ensitrelvir shortens the duration of two unpleasant symptoms of COVID-19: loss of smell and taste. The medication is among the first to alleviate these effects and, unlike other COVID-19 treatments, is not reserved only for people at high risk of severe illness. (Lenharo, 10/17)

In other news about covid —

CBS News: U.S. House Committee Investigating University Of Maryland COVID-19 Policy

A U.S. House committee is now investigating a COVID-19 policy at University of Maryland, College Park. Starting in September, if a student tests positive, they have to quarantine off campus. For students who live on campus, this means having to either go back to their family's home, or book lodging off campus like a hotel. Its cost falls squarely on the student's shoulders. (Valera, 10/16)

CBS News: Baltimore City To Provide Free COVID-19 Vaccines To Children And Adults On Fridays

The Baltimore City Health Department will offer new COVID-19 vaccines to children and adults at no cost. The offer extends to adults who are uninsured or underinsured. Now that COVID-19 infections are on the rise, the health department wants to make sure that everyone is staying safe. (Kushner, 10/17)

CIDRAP: COVID MRNA Vaccines Offer Strong Protection For Young Kids, Data Reveal 

A study yesterday in JAMA Network Open based on outcomes seen among Singaporean children ages 4 years and younger showed good protection for two doses of monovalent mRNA COVID vaccines during an Omicron surge. The authors said the findings support vaccinating this age-group, despite low incidence of severe disease or hospitalization. (Soucheray, 10/17)

Forbes: Pathize App Uses Biometrics To Help Long Covid Patients Manage Their Fatigue

Earlier this week, Chicago-based Pathize Health launched its brand-new app which helps patients living with long Covid to better manage their fatigue by collecting real-time data. This is achieved through connectivity with the Apple Watch enabling patients to develop important insights into key areas such as energy management, activity logging and medication adherence. (Alexiou, 10/18)

KFF Health News: Covid Relief Payments Triggered Feds To Demand Money Back From Social Security Recipients 

As the nation reeled from covid-19, the federal government sent many Americans a financial lifeline. But some recipients say the covid relief payments have triggered financial distress by jeopardizing their Social Security benefits. The government has demanded they repay much larger amounts — thousands of dollars in benefits for the poor and disabled distributed by the Social Security Administration. (Hilzenrath and Fleischer, 10/18)

In related news —

The Wall Street Journal: Bosses Have A Problem: People Are Actually Using Sick Days

The bar for taking a sick day is getting lower, and some bosses say that’s a problem. U.S. workers have long viewed an unwillingness to take sick days as a badge of honor. That’s a laurel workers care much less about these days. The number of sick days Americans take annually has soared since the pandemic, employee payroll data show. Covid-19 and a rise in illnesses such as RSV, which can require days away from work, are one reason. Managers and human-resources executives also attribute the jump to a bigger shift in the way many Americans relate to their jobs.  (Chen, 10/17)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 22
  • Thursday, May 21
  • Wednesday, May 20
  • Tuesday, May 19
  • Monday, May 18
  • Friday, May 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF